Bellemin Jean-Marc 4
4 · IOVANCE BIOTHERAPEUTICS, INC. · Filed Jun 16, 2022
Insider Transaction Report
Form 4
Bellemin Jean-Marc
Chief Financial Officer
Transactions
- Exercise/Conversion
Common Stock
2022-06-14+18,850→ 18,850 total - Tax Payment
Common Stock
2022-06-14$7.73/sh−9,346$72,245→ 9,504 total - Award
Restricted Stock Units
2022-06-14+18,850→ 18,850 total→ Common stock (18,850 underlying)
Footnotes (7)
- [F1]This is the first vesting of the restricted stock units issued on June 14, 2021.
- [F2]Represents common stock owned by the Reporting Person, excluding common stock purchased pursuant to the Issuer's 2020 Employee Stock Purchase Plan.
- [F3]Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of restricted stock units. This is not an open market sale of securities.
- [F4]Represents common stock remaining after deducting the common stock withheld for taxes.
- [F5]Represents restricted stock units remaining after deducting the vested shares of common stock and common stock withheld for taxes as set forth in Table I above.
- [F6]Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
- [F7]Provided the Reporting Person is still employed with the Issuer on December 31, 2022, the remaining restricted stock units shall vest and be settled on such date.